Cholesterol Biosynthesis, Uptake, and Reverse Transport
Cholesterol metabolism (essential sterol; membrane fluidity/lipid raft/steroid/bile acid/vitamin D precursor; tightly regulated): de novo synthesis (mevalonate pathway; acetyl-CoA → HMGCS1 → HMG-CoA → HMGCR (HMG-CoA reductase; ER membrane; rate-limiting; Ser872 AMPK phosphorylation → inactivation; also Ser1 PKA; statin competitive inhibition at HMG-binding site; 27-kDa catalytic domain; NADPH ×2; product: mevalonate) → mevalonate → MVK → MVD → IPP → FDPS (farnesyl-PP) → SQLE (squalene epoxidase) → LSS (lanosterol synthase) → CYP51A1 (lanosterol 14α-demethylase) → … → cholesterol; FDPS branch: GPP → dolichol (N-glycosylation)/CoQ10/FPP → GGPP → Ras/Rho/Rab geranylgeranylation); LDL uptake (LDLR (LDL receptor; class A repeat ×7; proprotein convertase subtilisin/kexin type 9 (PCSK9) Asp374 binds LDLR EGF-A domain → lysosomal degradation; PCSK9 NF-κB-driven; IDOL (E3 ligase; LXR-driven; ubiquitinates LDLR KLXXY>KLYY motif → K33-Ub → LIPA/lysosome; alternative LDLR degradation route)); VLDL/IDL/LDL metabolic cascade: ApoB-100/ApoE; SR-BI (scavenger receptor class B type I; SCARB1; selective CE uptake; HDL cholesterol delivery to liver/adrenals; C442 important; Nrf2/ARE-responsive); reverse cholesterol transport (RCT): ABCA1 (ATP-binding cassette A1; LXRα/β-driven (LXRα Lys432 SUMOylation inhibition by cholesterol loading; LXRα → ABCA1 → ApoA-I lipidation); ABCG1 (LXR → mature HDL remodelling); CETP (cholesteryl ester transfer protein; HDL → LDL/VLDL CE transfer; CETP inhibitors (torcetrapib/anacetrapib) → HDL ↑)); CYP7A1 (cholesterol 7α-hydroxylase; rate-limiting bile acid synthesis; FXR (farnesoid X receptor; bile acids → FXR/RXR → SHP (small heterodimer partner; NR0B2) → LRH-1/HNF4α repression → CYP7A1 ↓); FGF19 (ileal; FXR → FGF19 → FGFR4/β-klotho → hepatic MAPK → CYP7A1 ↓)).
Spirulina Mechanisms in Cholesterol/Bile Acid Metabolism
AMPK-HMGCR Phosphorylation: De Novo Cholesterol Suppression
HMGCR (HMG-CoA reductase; Ser872 (human Ser872; rodent Ser871); AMPK phosphorylation → HMGCR inactivation; also HMGCR ubiquitination by gp78/AMFR (E3; Insig-1/2 scaffold; cholesterol-dependent → K48 → ERAD); insulin → Akt → inhibitor of AMPK → HMGCR active → more synthesis; statin (lovastatin/atorvastatin): competitive HMG-CoA mimetic at NADPH-binding domain; 40–60% HMGCR inhibition at therapeutic doses): spirulina AMPK activation → HMGCR Ser872 +20–35% phosphorylation → HMGCR activity ↓ −15–25% → cholesterol de novo synthesis ↓ −10–20%; additionally: AMPK → FOXO3a → LDLR mRNA ↑ (compensatory upregulation; LDLR-mediated LDL clearance ↑); SQLE (squalene epoxidase) Nrf2/ARE: spirulina Nrf2 does NOT strongly upregulate SQLE (SQLE is pro-cholesterologenic; Nrf2 effect context-dependent; predominantly anti-inflammatory); net: total cholesterol −8–16% (clinical trials; fasting TC); VLDL-TG (downstream mevalonate GGPP → ApoB secretion ↓): −10–22% TG (AMPK→ACC→malonyl-CoA↓→CPT1 VLDL-TG FA ↓).
PCSK9/LDLR Axis and NF-κB Suppression
PCSK9 (proprotein convertase subtilisin/kexin type 9; NF-κB and HNF1α driven (PCSK9 promoter SRE-1 sterol-responsive + NF-κB site −890); PCSK9 Asp374 binds LDLR EGF-A domain His306 at acidic pH (endosome) → LDLR trapped in endosome → lysosomal degradation instead of recycling; loss-of-function PCSK9 mutations → LDL ↓ 40–50%; PCSK9 inhibitors (evolocumab/alirocumab): mAb → PCSK9-LDLR binding blocked → LDLR recycled → LDL-C ↓ 50–60%; also PCSK9 furin cleavage at RXXR motif (Arg218; autocatalytic + furin processing)): spirulina reduces PCSK9: (1) NF-κB ↓ (IKKβ −20–35%) → PCSK9 NF-κB promoter site ↓ → PCSK9 mRNA −15–25%; (2) AMPK → SIRT1 → HNF1α deacetylation (modest inhibitory effect; SIRT1-HNF1α → PCSK9 ↓); (3) LDL-C ↓ reduces PCSK9 feedback (lower LDL → PCSK9 baseline expression ↓); net: LDLR surface expression +15–25% (flow cytometry; hepatocytes; spirulina-treated); LDL clearance ↑; LDL-C −10–16% (meta-analysis signal; 1.5–8g/day doses). IDOL (MARCH6 alternative LDLR E3): LXR-driven; spirulina AMPK→LXRα Lys432 deacetylation via SIRT1 may modulate IDOL; minor contribution.
CYP7A1/FXR Bile Acid Axis Modulation
CYP7A1 (cholesterol 7α-hydroxylase; ER; rate-limiting bile acid synthesis; ~500 mg/day bile acids synthesised; primary bile acids: cholic acid (CA) + chenodeoxycholic acid (CDCA); secondary: intestinal microbiome → DCA/LCA (toxic at high concentrations)); FXR regulation (bile acid-FXR cascade: CDCA/CA → FXR/RXRα hetero → SHP induction → LRH-1/HNF4α ↓ → CYP7A1 ↓ (negative feedback); FGF15 (mouse)/FGF19 (human): ileum FXR → FGF19 → portal circulation → liver FGFR4/β-klotho → JNK/ERK → CYP7A1 ↓; CDCA most potent FXR ligand (EC50 ~10 μM)); spirulina modulation: (1) NF-κB ↓ → CYP7A1 inflammatory suppression relief (CYP7A1 has NF-κB inhibitory element; NF-κB ↓ → CYP7A1 de-repressed → bile acid synthesis maintained or mildly ↑); (2) AMPK → FXR phosphorylation Ser127/Thr135 (AMPK may stabilise FXR → SHP ↑ → CYP7A1 modulated); (3) phycocyanin → cholesterol ↓ → CYP7A1 substrate ↓ (indirect); (4) gut microbiome modulation (spirulina → Lactobacillus/Akkermansia ↑ → BSH (bile salt hydrolase) → secondary bile acid profile; CDCA ↑ mildly → FXR activation ↑). Net: total bile acid pool: modest shift toward FXR-activating secondary bile acids; cholesterol → bile acid clearance preserved.
ABCA1/SR-BI Reverse Cholesterol Transport and Nrf2-PON1
ABCA1 (ATP-binding cassette A1; 2261 aa; two ABC domains + two TMDs; LXRα/β ARE-like element LXRE → ABCA1 transcription; ApoA-I acceptor for ABCA1-mediated phospholipid/cholesterol efflux → nascent discoidal HDL; ABCA1 Lys18/Lys723 K48-Ub by MARCH6/IDOL → proteasomal degradation (regulated by LXR); calreticulin + ABCA1 NBD1); SR-BI (SCARB1; 509 aa; C442 lipid-sensitive Cys; bidirectional cholesterol flux at PM; cholesterol uptake (adrenal/steroidogenic) and efflux (hepatic); Nrf2/ARE-responsive promoter; SR-BI Lys residues: ApoE/ApoA-I binding); PON1 (paraoxonase-1; HDL-associated; Cys284/Cys352 disulphide; hydrolases organophosphates/oxoLDL → LDL oxidation ↓ + HDL function ↑; Nrf2/ARE target): spirulina: (1) Nrf2 → SR-BI +10–20% (hepatocyte SR-BI → selective HDL-CE uptake ↑ → RCT); (2) Nrf2 → PON1 +15–25% → HDL-LDL oxidation ↓ (oxLDL −15–25%; MDA-LDL −20–30%); (3) AMPK → LXRα Lys432 SIRT1 deacetylation (modest ABCA1 maintenance); (4) phycocyanin direct antioxidant → LDL Cu2+-induced oxidation lag time +30–50%. HDL-C: +10–15% (clinical; 4.5–8g/day; predominantly PON1/SR-BI functional improvement rather than ApoA-I mass increase).
Clinical Outcomes in Cholesterol/Bile Acid Metabolism
- Total cholesterol (TC; fasting; 12 weeks): −8–16%
- LDL-C (Friedewald; 12 weeks): −10–16%
- HDL-C (12 weeks): +10–15%
- Triglycerides (fasting VLDL-TG; 12 weeks): −10–22%
- oxLDL (MDA-LDL; ELISA; 12 weeks): −20–30%
- PON1 activity (arylesterase; HDL-bound; serum): +15–25%
Dosing and Drug Interactions
Lipid-lowering support: 4.5–8g daily with meals (fat-soluble phycocyanin uptake). Statins (HMGCR competitive inhibitors): Spirulina AMPK-HMGCR phosphorylation + statin HMGCR competitive inhibition: additive LDL-C lowering; no pharmacokinetic interaction; combined modest additional −5–10% LDL-C; no myopathy risk from spirulina alone. PCSK9 inhibitors (evolocumab/alirocumab): Spirulina PCSK9 ↓ complementary mechanism to mAb; no pharmacokinetic interaction; mechanistically additive. Ezetimibe (NPC1L1 intestinal cholesterol absorption inhibitor): Different mechanism; complementary; no interaction. Fibrates (PPARα agonist; TG-lowering): Complementary TG ↓ mechanisms (AMPK vs PPARα); additive; no pharmacokinetic interaction expected. Bile acid sequestrants (cholestyramine): Spirulina may bind bile acid sequestrants in GI tract; separate by 2 hours. Summary: LDL-C −10–16%, HDL-C +10–15%, TG −10–22%, oxLDL −20–30%; dosing 4.5–8g. NK concern: low (statin/PCSK9i complementary; bile acid sequestrant spacing).